Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL321209 | 0.97 | ALDH1A1 (0.39) | ALDH1A1L3MBTL1TSHRTDP1 | |
| Hydrochloric Acid SCHEMBL11271021 | 0.94 | ALDH1A1 (0.38) | ALDH1A1L3MBTL1TSHRTDP1 | |
| Fluoride SCHEMBL27565651 | 0.94 | ALDH1A1 (0.38) | ALDH1A1L3MBTL1TSHRTDP1 | |
| Water SCHEMBL9500989 | 0.94 | ALDH1A1 (0.38) | ALDH1A1L3MBTL1TSHRTDP1 | |
| SCHEMBL1865841 | 0.94 | ALDH1A1 (0.38) | ALDH1A1L3MBTL1TSHRTDP1 | |
| Ammonia Solution, Strong SCHEMBL28334670 | 0.94 | ALDH1A1 (0.38) | ALDH1A1L3MBTL1TSHRTDP1 | |
| SCHEMBL576102 | 0.87 | ALDH1A1 (0.33) | ALDH1A1L3MBTL1 | |
| SCHEMBL3297818 | 0.85 | ALDH1A1 (0.32) | ALDH1A1L3MBTL1 | |
| 1,3-Propanediol SCHEMBL575506 | 0.83 | ATR (0.32) | ALDH1A1L3MBTL1 | |
| 1,4-Butanediol SCHEMBL576160 | 0.83 | ATR (0.32) | ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947770-B2 | blend of polycarbonate resin prepared from diphenylcarbonate and 2,2-bis(4-hydroxyphenyl)propane; polytetrafluoroethylene antidrip agent; tetrafluoroalkylsulfonate or hexafluorodialkylsulfonimide salt of Na, K, Cs, Li or a pyridium, pydridazinium, phosphonium, ammonium etc.; protective devices | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-05-24 | — | — | US | claimed |
| US-20080221241-A1 | Flame Retardant Polycarbonate Compositions | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2008-09-11 | — | — | US | claimed |
| US-9376379-B2 | Process for the synthesis of tetrafluoroethanesulfonic acid | SRF LIMITED (IN) | 2016-06-28 | — | — | US | disclosed |
| US-20150259281-A1 | PROCESS FOR THE SYNTHESIS OF TETRAFLUOROETHANESULFONIC ACID | SRF LIMITED (IN) | 2015-09-17 | — | — | US | disclosed |
| EP-2118194-B1 | FLAME RETARDANT POLYCARBONATE COMPOSITIONS | DU PONT (US) | 2014-12-03 | — | — | EP | disclosed |
| US-20140286849-A1 | Mixtures of Ammonia and Ionic Liquids | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2014-09-25 | — | — | US | disclosed |
| US-8715521-B2 | Absorption cycle utilizing ionic liquid as working fluid | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-05-06 | — | — | US | disclosed |
| US-8707720-B2 | Hybrid vapor compression-absorption cycle | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-04-29 | — | — | US | disclosed |
| WO-2014020614-A2 | PROCESS FOR THE SYNTHESIS OF TETRAFLUOROETHANESULFONIC ACID | SRF LIMITED (IN) | 2014-02-06 | — | — | WO | disclosed |
| US-8628644-B2 | Utilizing ionic liquids for hydrofluorocarbon separation | E I DU PONT NEMOURS AND COMPANY (US) | 2014-01-14 | — | — | US | disclosed |
| US-8568608-B2 | Vapor compression cycle utilizing ionic liquid as compressor lubricant | E I DU PONT DE NEMOURS AND COMPANY (US) | 2013-10-29 | — | — | US | disclosed |
| US-20070066854-A1 | Preparation of polytrimethylene ether glycol and copolymers thereof | THE CHEMOURS COMPANY FC, LLC | 2007-03-22 | — | — | US | disclosed |
| US-20070066852-A1 | Preparation of poly(tetramethylene) glycol | THE CHEMOURS COMPANY FC, LLC | 2007-03-22 | — | — | US | disclosed |
| US-20070066822-A1 | Ionic liquids | THE CHEMOURS COMPANY FC, LLC | 2007-03-22 | — | — | US | disclosed |
| US-20070066853-A1 | Preparation of poly(tetramethylene) glycol | E. I. DU PONT DE NEMOURS AND COMPANY | 2007-03-22 | — | — | US | disclosed |
| US-20070066834-A1 | Ionic liquids | E. I. DU PONT DE NEMOURS AND COMPANY | 2007-03-22 | — | — | US | disclosed |
| US-20070019708-A1 | Hybrid vapor compression-absorption cycle | E. I. DU PONT DE NEMOURS AND COMPANY | 2007-01-25 | — | — | US | disclosed |
| WO-2006124776-A2 | HYBRID VAPOR COMPRESSION-ABSORPTION CYCLE | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2006-11-23 | — | — | WO | disclosed |
| US-20060197053-A1 | Absorption cycle utilizing ionic liquid as working fluid | E. I. DU PONT DE NEMOURS AND COMPANY | 2006-09-07 | — | — | US | disclosed |
| WO-2006084262-A1 | ABSORPTION CYCLE UTILIZING IONIC LIQUID AS WORKING FLUID | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066853-A1 | Preparation of poly(tetramethylene) glycol | PARG, PUF60, TPR | ALDH1A1 2896/4885L3MBTL1 2316/4885TSHR 3729/4885 |
| US-20070066834-A1 | Ionic liquids | NUP205, PML, AQP4 | ALDH1A1 3482/4885L3MBTL1 3533/4885TSHR 3674/4885 |
| US-20070066854-A1 | Preparation of polytrimethylene ether glycol and copolymers thereof | PARG, PTGES3, PGD | ALDH1A1 840/4885L3MBTL1 3248/4885TSHR 4703/4885 |
| US-20070066822-A1 | Ionic liquids | AFF2, AFF1, ZYX | ALDH1A1 3728/4885L3MBTL1 857/4885TSHR 445/4885 |
| US-20070066852-A1 | Preparation of poly(tetramethylene) glycol | PARG, PUF60, TPR | ALDH1A1 2896/4885L3MBTL1 2316/4885TSHR 3729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.